Organon & Co. (NYSE:OGN) upgraded to “Hold” by Zacks Investment Research

Organon & Cie (NYSE: OGNGet a rating) has been upgraded by Zacks Investment Research from a “sell” to a “hold” rating in a research note released Saturday to investors, reports.

According to Zacks, “Organon is a healthcare company. It focuses on women’s health throughout their lives. Organon is based in JERSEY CITY, NJ”

Several other research analysts also commented on OGN. Morgan Stanley cut its price target on shares of Organon & Co. from $37.00 to $35.00 and set an “equal weight” rating on the stock in a Wednesday, April 6 report. The Goldman Sachs group launched a hedge on the shares of Organon & Co. in a report on Wednesday, April 27. They issued a “buy” rating and a price target of $40.00 on the stock. Five research analysts gave the stock a hold rating and five gave the stock a buy rating. According to data from, the company currently has an average rating of “Buy” and a consensus price target of $39.89.

Shares of NGO action opened at $34.77 on Friday. The company has a market capitalization of $8.82 billion and a P/E ratio of 6.54. Organon & Co. has a 1-year minimum of $27.25 and a 1-year maximum of $39.47. The company’s 50-day simple moving average is $34.81 and its 200-day simple moving average is $33.47.

Organon & Cie (NYSE: OGNGet a rating) last reported quarterly earnings data on Thursday, May 5. The company reported earnings per share of $1.65 for the quarter, beating the consensus estimate of $1.30 by $0.35. The company posted revenue of $1.57 billion for the quarter, compared to analysts’ estimates of $1.52 billion. Organon & Co. had a net margin of 21.43% and a negative return on equity of 1,899.41%. The company’s revenue increased 4.1% year over year. During the same period a year earlier, the company posted EPS of $1.56. As a group, stock analysts expect Organon & Co. to post earnings per share of 5.4 for the current year.

Several institutional investors and hedge funds have recently changed their positions in OGN. Western Pacific Wealth Management LP acquired a new equity stake in Organon & Co. during the fourth quarter worth approximately $25,000. Magnolia Capital Management Ltd. acquired a new position in Organon & Co. during Q4 worth $26,000. Cutler Group LP purchased a new stake in shares of Organon & Co. in Q4 for a value of approximately $27,000. Dixon Hughes Goodman Wealth Advisors LLC acquired a new equity stake in Organon & Co. in Q4 valued at approximately $29,000. Finally, MCF Advisors LLC bought a new position in shares of Organon & Co. during the first quarter worth approximately $29,000. 70.85% of the shares are currently held by institutional investors.

About Organon & Co. (Get a rating)

Organon & Co, a healthcare company, develops and delivers healthcare solutions through a portfolio of prescription therapies in the United States and internationally. Its portfolio of women’s health products includes birth control and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive.

Read more

Get a Free Copy of Zacks’ Research Report on Organon & Co. (OGN)

For more information on Zacks Investment Research’s research offerings, visit

Analyst Recommendations for Organon & Co. (NYSE: OGN)

Get news and reviews for Organon & Co. Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Organon & Co. and related companies with’s free daily email newsletter.

Comments are closed.